GSK2879552 - CAS 1401966-69-5
Catalog number: 1401966-69-5
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C23H28N2O2
Molecular Weight:
364.48
COA:
Inquire
Targets:
Histone Demethylase
Description:
GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells. It was just planed a Phase I/II trail by GSK against Myelodysplastic syndromes.
Publication citing BOC Sciences Products
1. Contaminants of emerging concern in a freeze-thaw river during the spring flood
2. The Correlation between 2-Acetyl-1-pyrroline Content, Biological Compounds and Molecular Characterization to the Aroma Intensities of Thai Local Rice
3. Development and comparison of gas chromatography–mass spectrometry techniques for analysis of flame retardants
4. Impaired Corneal Sensation and Nerve Loss in a Type 2 Rat Model of Chronic Diabetes Is Reversible With Combination Therapy of Menhaden Oil, α-Lipoic Acid, and Enalapril
5. Depressed perivascular sensory innervation of mouse mesenteric arteries with advanced age
6. Pharmaceutical Characterization of MyoNovin, a Novel Skeletal Muscle Regenerator: in silico, in vitro and in vivo Studies

>> More

Purity:
98%
Appearance:
Powder
Synonyms:
GSK2879552; UNII-GT77Z6Y09Z; GSK-2879552; GSK 2879552; GT77Z6Y09Z; 1401966-69-5; 4-((4-((((1R,2S)-2-Phenylcyclopropyl)amino)methyl)piperidin-1-yl)methyl)benzoic acid
Solubility:
DMSO: 31 mg/mL
Storage:
-20ºC Freeze
MSDS:
Inquire
Application:
GSK2879552 has been found to be a LSD1 inhibitor that could have antineoplastic effect through restraining the growth of overexpressed tumor cells.
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly
Quantity:
Millgrams-Grams
InChIKey:
LRULVYSBRWUVGR-FCHUYYIVSA-N
InChI:
InChI=1S/C23H28N2O2/c26-23(27)20-8-6-18(7-9-20)16-25-12-10-17(11-13-25)15-24-22-14-21(22)19-4-2-1-3-5-19/h1-9,17,21-22,24H,10-16H2,(H,26,27)/t21-,22+/m0/s1
Canonical SMILES:
C1CN(CCC1CNC2CC2C3=CC=CC=C3)CC4=CC=C(C=C4)C(=O)O
Current Developer:
GSK
1.Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment.
Zheng YC;Yu B;Jiang GZ;Feng XJ;He PX;Chu XY;Zhao W;Liu HM Curr Top Med Chem. 2016;16(19):2179-88.
Due to the increasing costs and time consuming for new drug discovery, a large number of pharmaceutical firms have chosen to modify the existing drug molecules for repositioning candidates with new or improved properties, especially those with severe adverse effects, thereby accelerating the drug discovery process. Such strategy has witnessed its success with several examples reported. As the first identified histone lysine specific demethylase, lysine specific demethylase 1 (LSD1) is classified as a member of monoamine oxidase (MAO) superfamily, and specifically removes mono- and dimethylated histone 3 lysine 4 (H3K4) and H3 lysine 9 (H3K9). It has been reported that LSD1 and its downstream targets are involved in cancer cell growth and metastasis. Meanwhile, it is overexpressed in a variety of tumor cells. Inactivating LSD1 specifically inhibits tumor progression and metastasis. Hence, LSD1 inhibition may represent a new and promising direction in anti-cancer drug discovery. Based on the structure and cofactor of LSD1, some clinical applied MAO inhibitors have been identified as LSD1 inactivators. Among them, tranylcypromine presented the most potency against LSD1 and its derivatives were further developed by medicinal chemists in order to develop potent and selective LSD1 inhibitors.
2.Design, synthesis and biological evaluation of [1,2,4]triazolo[1,5-a]pyrimidines as potent lysine specific demethylase 1 (LSD1/KDM1A) inhibitors.
Wang S;Zhao LJ;Zheng YC;Shen DD;Miao EF;Qiao XP;Zhao LJ;Liu Y;Huang R;Yu B;Liu HM Eur J Med Chem. 2017 Jan 5;125:940-951. doi: 10.1016/j.ejmech.2016.10.021. Epub 2016 Oct 14.
A new series of [1,2,4]triazolo[1,5-a]pyrimidine-based LSD1 inhibitors were designed, synthesized, and further evaluated for their cytotoxicity against MGC-803, EC109, A549 and PC-9 cells as well as the ability of inhibiting LSD1. Some of these compounds showed potent inhibition toward LSD1 and selectively inhibited growth of A549 and PC-9 cells. Compound 6l potently inhibited growth of PC-9 cells (IC;50; = 0.59 μM), about 4-fold more potent than 5-FU. Further SARs studies led to the identification of compounds 6l-m, which had good growth inhibition against all the tested cancer cell lines and were much more potent than 5-FU and GSK2879552. Besides, compounds 5p, 5q and 6i inhibited LSD1 potently (IC;50; = 0.154, 1.19 and 0.557 μM, respectively). Docking studies revealed that compound 5p formed arene-H interactions with Val333 and hydrogen bonds with surrounding Ala331, Met332, and Ala539 residues. Compound 5p significantly inhibited migration of A549 and PC-9 cells in a concentration-dependent manner, but had different effect on the expression of E-cadherin and N-cadherin. The [1,2,4]triazolo[1,5-a]pyrimidine scaffold may serve as a starting point for developing potent LSD1 inhibitors for cancer therapy.
3.Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes.
Lillico R;Lawrence CK;Lakowski TM J Proteome Res. 2018 Aug 3;17(8):2657-2667. doi: 10.1021/acs.jproteome.8b00118. Epub 2018 Jul 17.
Mixed lineage leukemia results from chromosomal rearrangements of the gene mixed lineage leukemia (MLL). MLL-AF9 is one such rearrangement that recruits the lysine methyltransferase, human disruptor of telomere silencing 1-like (DOT1L) and lysine specific demethylase 1 (LSD1), resulting in elevated expression of the Homeobox protein A9 (HOXA9), and leukemia. Inhibitors of LSD1 or DOT1L reduce HOXA9 expression, kill MLL-rearranged cells, and may treat leukemia. To quantify their effects on histone modifying enzyme activity and expression in MLL-rearranged leukemia, we tested inhibitors of DOT1L (EPZ-5676), LSD1 (GSK2879552), and HDAC (mocetinostat), in the MLL-AF9 cell line MOLM-13. All inhibitors reduced MOLM-13 viability but only mocetinostat induced apoptosis. EPZ-5676 increased total histone lysine dimethylation, which was attributed to a reduction in LSD1 expression, and was indistinguishable from direct LSD1 inhibition by GSK2879552. All compounds directly inhibit, or reduce the expression of, HOXA9, DOT1L and LSD1 by qPCR, increase total histone lysine methylation and acetylation by LC-MS/MS, and specifically reduce H3K79Me2 and increase H3K14Ac. Each inhibitor altered the expression of many histone modifying enzymes which may precipitate additional changes in expression.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Histone Demethylase Products

CAS 2003260-55-5 NCGC00244536

NCGC00244536
(CAS: 2003260-55-5)

NCGC00244536 is a potent KDM4A inhibitor (IC50= 10 nM) that inhibits the in vivo growth of tumors derived from PC3 cells and ex vivo human PCa explants.

CAS 1423715-09-6 SP2509

SP2509
(CAS: 1423715-09-6)

SP2509 inhibits the association of LSD1 with CoREST, increases promoter-specific H3K4Me3 and induces p53, p21 and C/EBPα. SP2509 also significantly inhibits the...

KDM5-inhibitor

KDM5-inhibitor is an analog of CPI-455, a selective KDM5 inhibitor. CPI-455 increases levels of H3K4 trimethylation (H3K4me3) and decreases the number of DTPs i...

CAS 199596-24-2 (Z)-JIB-04

(Z)-JIB-04
(CAS: 199596-24-2)

(Z)-JIB-04 is a Z-isomer of JIB-04, which is a small-molecule histone demethylase inhibitor with antitumor activity. JIB-04 selectively inhibits tumor growth vi...

CAS 1628208-23-0 CPI 455

CPI 455
(CAS: 1628208-23-0)

CPI 455 is a selective inhibitor of KDM5 demethylases (IC50 value 10 nM for inhibition of full length KDM5A) that specifically alters H3K4 methylation (H3K4me3)...

CAS 1222800-79-4 ML324

ML324
(CAS: 1222800-79-4)

ML324 exhibits good Caco-2 cell permeability, and possesses excellent microsomal stability in the presence of both mouse and rat liver microsomes.

CAS 1628210-26-3 KDM5-IN-1

KDM5-IN-1
(CAS: 1628210-26-3)

KDM5-IN-1 is a potent and selective KDM5 inhibitor with modest cell activity (PC9 H3K4Me3 EC50 = 5.2 μM).

CAS 1616392-22-3 GSK3326595

GSK3326595
(CAS: 1616392-22-3)

GSK3326595, also called as EPZ015938, is an orally available and specific inhibitor of protein arginine methyltransferase 5 (PRMT5) that potently inhibits tumor...

Chemical Structure

CAS 1401966-69-5 GSK2879552

Quick Inquiry

Verification code

Featured Items